Latest Breaking News On - சாயலும் உயிர் அறிவியல் - Page 1 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights Fortress Biotech, Inc.May 16, 2021 GMT Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma by year-end 2021 Ended first quarter 2021 with $291.5 million in consolidated cash, cash equivalents and restricted cash NEW YORK, May 16, 2021 (GLOBE NEWSWIRE) Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced financial results and recent corporate highlights for the first quarter ended March 31,

United statesMazyar shadmanJaclyn jaffeCaelum biosciencesMarkus petersLindsaya rosenwaldTony plohorosCyprium therapeutics incTechnology fastEuropean hematology associationVirtual congressCaelum biosciences incFred hutchinson cancer research centerCompany contactsLifesci advisorsCheckpoint therapeutics inc